Skip to main content

Advertisement

SpringerLink
Log in

Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

BackgroundAndrogen deprivation therapy (ADT) is essential in the treatment of advanced and metastatic prostate cancer. As the correlation between hormone therapy and hypertension remains unclear and prostate cancer is less prevalent in the Asian population, the clinician should focus on not only anticancer therapy but also the side effects of the intervention and quality of life of these patients.ObjectiveThis study aimed to investigate the risk of subsequent hypertension in patients undergoing androgen deprivation therapy for prostate cancer.Setting Data of 10,843 patients with prostate cancer were retrospectively collected from the Longitudinal Health Insurance Database of Taiwan. The institutional review board of Kaohsiung Medical University Hospital approved our study.Method In propensity score matching, 3001 patients with prostate cancer aged ≥ 40 years who underwent androgen deprivation therapy were included in the study cohort (androgen deprivation therapy-ever), and 3001 patients with cancer who did not undergo androgen deprivation therapy were included in the control group (androgen deprivation therapy-never), after adjusting for age and other comorbidities.Main outcome measure The event of new-onset hypertension between the study cohort and control cohort.ResultsDuring the average 5-year follow-up period, the incidence rates of new-onset hypertension were 22.6 and 33.0 per 1000 person-years in the androgen deprivation therapy-never and androgen deprivation therapy-ever cohorts, respectively. The androgen deprivation therapy-ever cohort was found to be 1.78 times more likely to develop new-onset hypertension than was the control group (95% confidence interval [CI], 1.61–1.96; P < 0.001). Moreover, the subgroup of combined androgen blockade had almost doubled the risk of subsequent hypertension (adjusted hazard ratio, 1.93; 95% CI 1.71–2.18; P < 0.001).ConclusionsOur study suggests that men with prostate cancer who underwent androgen deprivation therapy are at risk of developing hypertension in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  Google Scholar 

  2. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3):581–8.

    Article  CAS  Google Scholar 

  3. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.

    Article  CAS  Google Scholar 

  4. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–83.

    Article  Google Scholar 

  5. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113(5):1097–106.

    Article  CAS  Google Scholar 

  6. Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–36.

    Article  CAS  Google Scholar 

  7. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50.

    Article  Google Scholar 

  8. Campbell NR, Lackland DT, Lisheng L, Niebylski ML, Nilsson PM, Zhang XH. Using the Global Burden of Disease study to assist development of nation-specific fact sheets to promote prevention and control of hypertension and reduction in dietary salt: a resource from the World Hypertension League. J Clin Hypertens. (Greenwich Conn). 2015;17(3):165–7.

    Article  Google Scholar 

  9. Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171(6 Pt 1):2285–90.

    Article  Google Scholar 

  10. Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol. 2012;62(5):757–64.

    Article  CAS  Google Scholar 

  11. Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, et al. Low free testosterone and prostate cancer risk: a collaborative analysis of 20 prospective studies. Eur Urol. 2018;74(5):585–94.

    Article  CAS  Google Scholar 

  12. Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013;217(3):R47–71.

    Article  CAS  Google Scholar 

  13. Chou TM, Sudhir K, Hutchison SJ, Ko E, Amidon TM, Collins P, et al. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation. 1996;94(10):2614–9.

    Article  CAS  Google Scholar 

  14. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261–7.

    Article  CAS  Google Scholar 

  15. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2):195–201.

    Article  CAS  Google Scholar 

  16. Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Rajkumar C. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J Androl. 2009;30(4):410–5.

    Article  CAS  Google Scholar 

  17. Oka R, Utsumi T, Endo T, Yano M, Kamijima S, Kamiya N, et al. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. Int J Clin Oncol. 2016;21(2):389–96.

    Article  CAS  Google Scholar 

  18. Nowicki M, Bryc W, Kokot F. Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. J Endocrinol Investig. 2001;24(1):31–6.

    Article  CAS  Google Scholar 

  19. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71(2):318–22.

    Article  Google Scholar 

  20. Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1–7.

    Article  CAS  Google Scholar 

  21. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–7.

    Article  CAS  Google Scholar 

  22. Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, et al. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int. 2011;107(6):929–35.

    Article  Google Scholar 

  23. Liang Z, Xie B, Li J, Wang X, Wang S, Meng S, et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:31358.

    Article  CAS  Google Scholar 

  24. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Investig. 2013;36(2):132–9.

    Article  CAS  Google Scholar 

  25. Stocks T, Van Hemelrijck M, Manjer J, Bjorge T, Ulmer H, Hallmans G, et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension. 2012;59(4):802–10.

    Article  CAS  Google Scholar 

  26. Berger SM, Gislason G, Moore LL, Andersson C, Torp-Pedersen C, Denis GV, et al. Associations between metabolic disorders and risk of cancer in Danish men and women–a nationwide cohort study. BMC Cancer. 2016;16:133.

    Article  Google Scholar 

  27. Harding JL, Sooriyakumaran M, Anstey KJ, Adams R, Balkau B, Brennan-Olsen S, et al. Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. J Hypertens. 2016;34(1):149–55.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the Department of Internal Medicine and the Statistical Analysis Laboratory in the Department of Medical Research at Kaohsiung Medical University Hospital.

Funding

The study was supported by grants from Kaohsiung Medical University Hospital (KMUH-107-7M28).

Author information

Author notes

    Authors and Affiliations

    1. Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

      Yi-Hsuan Wu, Jhen-Hao Jhan, Hung-Lung Ke, Hsin-Chih Yeh, Ching-Chia Li & Yung-Chin Lee

    2. Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

      Yi-Hsuan Wu, Jhen-Hao Jhan, Hung-Lung Ke, Hsin-Chih Yeh, Ching-Chia Li & Yung-Chin Lee

    3. Department of Urology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan

      Yi-Hsuan Wu, Jhen-Hao Jhan & Yung-Chin Lee

    4. Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

      Yi-Hsuan Wu, Jhen-Hao Jhan, Hung-Lung Ke, Shih-I Tseng, Hsin-Chih Yeh, Ching-Chia Li & Yung-Chin Lee

    5. Management Offices, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan

      Yu-Han Chang

    6. Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan

      Hsin-Chih Yeh

    Authors
    1. Yi-Hsuan Wu
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Jhen-Hao Jhan
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Hung-Lung Ke
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Shih-I Tseng
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Yu-Han Chang
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Hsin-Chih Yeh
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Ching-Chia Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Yung-Chin Lee
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Yung-Chin Lee.

    Ethics declarations

    Conflicts of interest

    There are no conflicts of interest.

    Additional information

    Publisher's note

    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Wu, YH., Jhan, JH., Ke, HL. et al. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study. Int J Clin Pharm 42, 1433–1439 (2020). https://doi.org/10.1007/s11096-020-01143-9

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s11096-020-01143-9

    Keywords

    Search

    Navigation